US-based AVEO Oncology, an LG Chem (KRX:051910) company, announced on Wednesday that the 20mg/kg dose of ficlatuzumab has been chosen for the combination arm of the Phase 3 registrational FIERCE-HN clinical trial following the planned first interim analysis.
The ongoing FIERCE-HN trial continues to enrol patients with human papillomavirus (HPV)-negative recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) and aims to recruit 410 to 500 patients.
The global, multicentre, randomised, double-blind, placebo-controlled Phase 3 clinical trial is evaluating ficlatuzumab in combination with ERBITUX (cetuximab), an anti-epidermal growth factor receptor (EGFR) antibody, as compared to placebo plus cetuximab, in patients with HPV-negative R/M HNSCC.
Ficlatuzumab is AVEO's investigational antibody that targets hepatocyte growth factor (HGF).
Reacta Healthcare names new chair of board
Lario Therapeutics awarded USD2.4m in grants for neuronal calcium channel research
EMA validates Enhertu application for post-neoadjuvant HER2-positive early breast cancer
Merck reports positive Phase 3 data for Enflonsia in high-risk children across two RSV seasons
IBA and Shreeji sign agreement to deploy four cyclotrons for PET radiopharmaceuticals in India
AVEO Oncology completes first interim analysis in global Phase 3 FIERCE-HN study
Cedar Health Research opens new embedded research site within Texas Native Health
Merck and Mayo Clinic launch AI-driven drug discovery collaboration